Net Present Value Model: Tislelizumab
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Tislelizumab Drug Details
Tislelizumab (Baizean) is a humanized monoclonal antibody that belongs to a class of immuno-oncology agents. It is formulated as powder for solution for intravenous route of administration. Baizean is used for the treatment of patients with classical Hodgkin’s lymphoma (cHL) who have received at least two prior therapies and treatment for patients with locally advanced or metastatic urothelial carcinoma (UC). It is also indicated as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Baizean is indicated for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, including patients with advanced colorectal cancer (CRC) who had been treated with fluoropyrimidine, oxaliplatin and irinotecan and other advanced solid tumors who develop disease progression after prior treatment and have no satisfactory alternative treatment options. Baizean is indicated as a treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression or are intolerant to first-line standard chemotherapy. Tislelizumab, in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC). It is aslo indicated to treat cancers associated with homologous-recombination deficient (HRD).Tislelizumab is under development for the treatment of locally advanced rectal cancer, hepatocellular carcinoma (HCC), acute myelocytic leukemia, relapsed and refractory acute myeloid leukemia, high-risk myelodysplastic syndromes, primary mediastinal large B-cell lymphoma, triple negative breast cancer (TNBC), gallbladder cancer, pancreatic ductal adenocarcinoma, locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer, esophageal squamous cell carcinoma, melanoma, metastatic esophageal, HER2 positive breast cancer, gastric, or gastroesophageal junction carcinoma (as a first line therapy), squamous non-small cell lung cancer, advanced solid tumors such as triple negative breast cancer, ovarian cancer, colorectal cancer, cervical cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, non-squamous non-small cell lung cancer, sarcomas, endometrial cancer, cholangiocarcinoma, brain metastasis, chronic lymphocytic leukemia (CLL), follicular lymphoma, aggressive lymphoma, including diffuse large B-cell lymphoma (DLBCL), renal cell carcinoma, squamous cell carcinoma, cutaneous squamous cell carcinoma, adrenocorticoid carcinoma, thyroid cancer, metastatic esophageal squamous cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, mesothelioma, adenocarcinoma of mandible, undifferentiated adenocarcinoma from teratoma, blood borne cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, small-cell lung cancer, peritoneal cancer, fallopian tube cancer, muscle invasive bladder cancer (MIBC), metastatic adenocarcinoma of the pancreas, non-small cell lung cancer, T-cell lymphomas such as angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma-NOS, anaplastic T-cell lymphoma, Extranodal NK/T-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), relapsed or refractory classical Hodgkin lymphoma (cHL), mycosis fungoides, gastrointestinal stromal tumor (GIST), mantle cell lymphoma, marginal zone B cell lymphoma, adenoid cystic carcinoma, nasopharyngeal cancer, sezary syndrome, renal pelvis cancer, ureter cancer, bladder cancer, nasopharyngeal cancer, oral cavity cancer or urethral cancer. It is administered by intravenous drip route. The drug candidate is a highly selective and potent, humanized anti-PD-1 monoclonal antibody. It was also under treatment for the treatment of duodenal cancer, anal squamous cell cancer, glioblastoma multiforme, Waldenstrom macroglobulinemia.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.